Is Protalix BioTherapeutics, Inc. (PLX) a Buy, Sell, or Hold?
AMEX : PLX
Protalix BioTherapeutics, Inc.
$2.5864 USD
$0.16 (6.66%)
- Volume
- 1.76M
- Average Volume
- 697.46K
- Market Capitalization
- $208.39M
- P/E Ratio
- 10.73
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.19
- Year Low
- $1.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.94
Company Overview
AMEX
Dror Bashan
Biotechnology
Healthcare
PLX
226
US
USD
Liquidity Metrics
0.09
2.94
1.91
0.87
0.00
Sales & Valuation
$52.74M
2.58
2.01
27.18
0.10
Profitability
-$0.0841
-$6.6M
23.50%
29.10%
27.95%
17.17%
P/E Metrics
10.73
-0.02
-0.02
Analyst Price Target & Rating
4/5
7 Analysts
%
Financial Health Scores
0.44
6/9
$58.97M
$102.34M
$35.11M
$20.8M
Key Metrics (TTM)
$162.56M
2.13
7.28
3.15
28.10%
20.62%
7.90%
6.64%
$1.91
431 days
Company Executives
| Name | Title |
|---|---|
| Gilad Mamlok | Senior VP, CFO Treasurer & Secretary |
| Yaron Naos | SVP & COO |
| Dror Bashan | President, Chief Executive Officer & Director |
| Yael Fellous | Vice President of Human Resources |
Poll Results
No votes yet today — be the first to share your view!
About Protalix BioTherapeutics, Inc. (AMEX:PLX) Stock
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix Bio ... Therapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
2026-08-12 13:57:10
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-12 06:50:00
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 million The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.
2026-08-05 06:50:00
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
2026-05-13 11:50:44
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
2026-05-13 06:50:00
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027 The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, May 13, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update.
Frequently Asked Questions
-
What is the current Protalix BioTherapeutics, Inc. (PLX) stock price?
-
Protalix BioTherapeutics, Inc.(AMEX:PLX) stock price is $2.5864 in the last trading session. During the trading session, PLX stock reached the peak price of $3.19 while $1.46 was the lowest point it dropped to. The percentage change in PLX stock occurred in the recent session was 6.66% while the dollar amount for the price change in PLX stock was $0.16.
-
PLX's industry and sector of operation?
-
The AMEX listed PLX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PLX?
-
Gilad Mamlok | Senior VP, CFO Treasurer & Secretary
Yaron Naos | SVP & COO
Dror Bashan | President, Chief Executive Officer & Director
Yael Fellous | Vice President of Human Resources
| -
How many employees does PLX have?
-
Number of PLX employees currently stands at 226. PLX operates from 2 University Plaza, Hackensack, NJ 07601, US.
-
Link for PLX official website?
-
Official Website of PLX is: https://www.protalix.com
-
How do I contact PLX?
-
PLX could be contacted at phone #201 696 9345 and can also be accessed through its website. PLX operates from 2 University Plaza, Hackensack, NJ 07601, US.
-
How many shares of PLX are traded daily?
-
The average number of PLX shares traded daily for last 3 months was 697.46K.
-
What is the market cap of PLX currently?
-
The market value of PLX currently stands at $208.39M with its latest stock price at $2.5864